The Ritedose Corp., a CDMO specializing in sterile Blow Fill Seal (BFS) production, is significantly expanding its production capabilities to meet demand for ophthalmic and respiratory medications.
 
The expanded sterile BFS capabilities and new equipment is expected to begin production in August of this year. The addition of another 180-million-unit dose capacity for ophthalmic and respiratory medications aims to meet increasing demand from ophthalmic and respiratory drug developers for high-quality, sterile unit dose solutions.
 
The new capacity will be integrated into Ritedose’s state-of-the-art manufacturing facility in Columbia, SC. The facility is equipped with the latest technology and staffed by a team of skilled professionals. This strategic expansion enhances the company’s ability to serve its customers more efficiently and ensure a consistent supply of critical medications. 
 
This expansion marks a pivotal moment in our company’s history,” said CEO of Ritedose Jody Chastain. “We’re passionately dedicated to advancing the health and well-being of patients across the United States—it’s why we come to work every single day. We are perfectly positioned to support our partners and deliver quality medications, and both they and our patients count on us to be steps ahead in capacity, capabilities and without a doubt, quality. It’s our forward-looking strategy and commitment that has allowed us to maintain a 100% customer retention rate over the past 25 years.”